Yesim Ozguler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yesim Ozguler has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
- Gulen Hatemi
Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa , Istanbul, Türkiye
19 shared publications Gulen Hatemi
Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology
13 shared publications- Sinem Nihal Esatoglu
Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa , Istanbul, Türkiye
11 shared publications - Vedat Hamuryudan
Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa , Istanbul, Türkiye
11 shared publications Hasan Yazici
Academic Hospital, Istanbul, Türkiye
10 shared publications- Serdal Ugurlu
Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine Istanbul University‐Cerrahpasa Istanbul Turkey
10 shared publications
Latest Publications
- 27 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
Current management of Behçet syndrome
Purpose of review: To summarize the most clinically relevant recent advances in the treatment of Behçet syndrome (BS), with emphasis on the updated 2025 EULAR recommendations and emerging evidence across different organ manifestations. Recent findings: The updated EULAR recommendations support earlier use of monoclonal TNF inhibitors (TNFi), particularly in severe ocular, vascular, and neurologic involvement, and favor their continued use for maintenance in selected major-organ disease. Recent randomized and comparative studies provide further support for TNFi in Behçet uveitis and vascular involvement. Newer agents, including PDE-4 inhibitors and JAK inhibitors (JAKi), have shown promising efficacy in mucocutaneous, gastrointestinal, ocular, vascular, and neurologic disease, although most evidence for JAKi remains derived from small uncontrolled studies. Ustekinumab has also shown encouraging results in refractory intestinal BS. The role of anticoagulation in vascular BS remains uncertain. Summary: Management of BS is increasingly organ- and risk-adapted, with earlier use of effective targeted therapies in patients at risk of irreversible damage. Despite encouraging results with several newer agents, comparative and high-quality evidence remains limited, highlighting the need for adequately powered studies with organ-specific outcomes.
- 27 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
Current management of Behçet syndrome
Purpose of review: To summarize the most clinically relevant recent advances in the treatment of Behçet syndrome (BS), with emphasis on the updated 2025 EULAR recommendations and emerging evidence across different organ manifestations. Recent findings: The updated EULAR recommendations support earlier use of monoclonal TNF inhibitors (TNFi), particularly in severe ocular, vascular, and neurologic involvement, and favor their continued use for maintenance in selected major-organ disease. Recent randomized and comparative studies provide further support for TNFi in Behçet uveitis and vascular involvement. Newer agents, including PDE-4 inhibitors and JAK inhibitors (JAKi), have shown promising efficacy in mucocutaneous, gastrointestinal, ocular, vascular, and neurologic disease, although most evidence for JAKi remains derived from small uncontrolled studies. Ustekinumab has also shown encouraging results in refractory intestinal BS. The role of anticoagulation in vascular BS remains uncertain. Summary: Management of BS is increasingly organ- and risk-adapted, with earlier use of effective targeted therapies in patients at risk of irreversible damage. Despite encouraging results with several newer agents, comparative and high-quality evidence remains limited, highlighting the need for adequately powered studies with organ-specific outcomes.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-13
Elucidating the Role of Neutrophils in the Inflammatory Response to Behcet Syndrome
Behçet syndrome (BS) is a chronic, relapsing, multisystem inflammatory disorder in which both innate and adaptive immune mechanisms contribute to disease pathogenesis. Among innate immune cells, neutrophils have emerged as key effectors driving tissue inflammation, endothelial injury, and immunothrombosis. Early studies demonstrated enhanced chemotaxis, oxidative burst, and a primed activation state of circulating neutrophils, whereas more recent evidence highlights excessive neutrophil extracellular trap (NET) formation as an important contributor to vascular inflammation and thrombosis. In addition, recent omics-based studies have provided novel insights into neutrophil heterogeneity, activation pathways, and disease-specific signatures in BS. This review summarizes current knowledge on the role of neutrophils and NETs in the pathogenesis of BS, summarizes available evidence on mechanisms of neutrophil activation, and highlights potential directions for future research.
- 1 May 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-13
Open AccessElucidating the Role of Neutrophils in the Inflammatory Response to Behcet Syndrome
Behçet syndrome (BS) is a chronic, relapsing, multisystem inflammatory disorder in which both innate and adaptive immune mechanisms contribute to disease pathogenesis. Among innate immune cells, neutrophils have emerged as key effectors driving tissue inflammation, endothelial injury, and immunothrombosis. Early studies demonstrated enhanced chemotaxis, oxidative burst, and a primed activation state of circulating neutrophils, whereas more recent evidence highlights excessive neutrophil extracellular trap (NET) formation as an important contributor to vascular inflammation and thrombosis. In addition, recent omics-based studies have provided novel insights into neutrophil heterogeneity, activation pathways, and disease-specific signatures in BS. This review summarizes current knowledge on the role of neutrophils and NETs in the pathogenesis of BS, summarizes available evidence on mechanisms of neutrophil activation, and highlights potential directions for future research.
- Top Cited PapersOpen Access
- 8 April 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (2) , 100152
Management of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations
- 8 April 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (2) , 100152
Top Cited PapersOpen AccessManagement of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations
- Open Access
- 3 April 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (2) , 100158
Work productivity in Behçet syndrome
- 3 April 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (2) , 100158
Open AccessWork productivity in Behçet syndrome
- Top Cited PapersOpen Access
- 23 March 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (6) , 1010-1025
EULAR recommendations for the management of Behçet’s syndrome: 2025 update
- 23 March 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (6) , 1010-1025
Top Cited PapersOpen AccessEULAR recommendations for the management of Behçet’s syndrome: 2025 update
- Open Access
Venous vessel-wall assessment with superb microvascular imaging in Behçet syndrome
Objectives Superb microvascular imaging (SMI) provides a more sensitive assessment of small vessels compared with power and colour Doppler ultrasonography (PDUS and CDUS). We aimed to investigate the potential of SMI for use in research and clinical practice in Behçet syndrome (BS) and to gain a better understanding of erythema nodosum (EN) like and superficial thrombophlebitis (STM) lesions using SMI. Methods We studied 51 patients with BS and 31 patients with non-BS with red palpable lesions on physical examination. B-mode US, CDUS, PDUS and SMI were performed and recorded by the same radiologist and recorded images were additionally evaluated independently by another radiologist. Vessel-wall signal intensity of STM lesions by SMI was graded in four groups according to the percentages of the affected vessel-wall area (Grade 0: no signal, Grade 1: < 25%, Grade 2: 25%–50%, Grade 3: 50%–75% and Grade 4: >75%). Results The lesions of 26 patients with BS and 17 patients with non-BS were diagnosed as STM with CDUS. SMI of STM lesions revealed vessel-wall signals in 21/26 patients with BS (81%), in contrast to only 3/17 (18%) patients with non-BS. While 16 of 21 patients with BS (76%) had at least grade 2 signal, only 1 of 3 non-BS had it. Lesions of 25 BS and 11 non-BS were diagnosed as EN by CDUS and SMI showed no vessel-wall signal in these patients. Conclusions Evaluation of the vessel wall with SMI in BS may be a promising approach for showing inflammation as an inexpensive, non-invasive and reliable imaging method that does not require a contrast agent.
Open AccessVenous vessel-wall assessment with superb microvascular imaging in Behçet syndrome
Objectives Superb microvascular imaging (SMI) provides a more sensitive assessment of small vessels compared with power and colour Doppler ultrasonography (PDUS and CDUS). We aimed to investigate the potential of SMI for use in research and clinical practice in Behçet syndrome (BS) and to gain a better understanding of erythema nodosum (EN) like and superficial thrombophlebitis (STM) lesions using SMI. Methods We studied 51 patients with BS and 31 patients with non-BS with red palpable lesions on physical examination. B-mode US, CDUS, PDUS and SMI were performed and recorded by the same radiologist and recorded images were additionally evaluated independently by another radiologist. Vessel-wall signal intensity of STM lesions by SMI was graded in four groups according to the percentages of the affected vessel-wall area (Grade 0: no signal, Grade 1: < 25%, Grade 2: 25%–50%, Grade 3: 50%–75% and Grade 4: >75%). Results The lesions of 26 patients with BS and 17 patients with non-BS were diagnosed as STM with CDUS. SMI of STM lesions revealed vessel-wall signals in 21/26 patients with BS (81%), in contrast to only 3/17 (18%) patients with non-BS. While 16 of 21 patients with BS (76%) had at least grade 2 signal, only 1 of 3 non-BS had it. Lesions of 25 BS and 11 non-BS were diagnosed as EN by CDUS and SMI showed no vessel-wall signal in these patients. Conclusions Evaluation of the vessel wall with SMI in BS may be a promising approach for showing inflammation as an inexpensive, non-invasive and reliable imaging method that does not require a contrast agent.
- Open Access
- 25 January 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-10
Safety outcome trials in four mainline medical journals 30 years apart: a narrative review and the need for the transparency of informed consents
It was our impression that safety outcome trials were getting more frequent, raising ethical issues mainly related to patient autonomy. We and others had also proposed this autonomy would be best served if wording of the informed consents would be in the public domain. Initially two observers and an arbiter tabulated the main aims of randomized controlled trials (RCTs) published in 1990–1991 vs. 2019–2020 as efficacy, safety, or undecided in four mainline medical journals, from the websites. A pragmatic design as well as other salient features was also tabulated. After noting too many trials were categorized as undecided, two additional independent observers and the arbiter did a reassessment. In our reassessment of 889 RCTs, 309 in earlier and 580 in the later time period, 828 (93%) were categorized as efficacy and 47 (5%) as a safety trial. We were undecided in 14 (2%) trials. The proportion of safety outcome trials between the two time periods were similar [14/309 (5%) vs. 33/580 (6%)] while RCTs of any category conducted in the critical care settings notably increased in time [12/309 (4%) vs. 52/580 (9%) OR 2.4; 1.3–4.6]. Death was a primary outcome measure in 0/14 among the earlier and 16/33 (49%) among the later safety outcome trials. Stroke in 9 and myocardial infarction in 8 safety outcome trials were additional primary outcome measures in the same group. There were 2 pragmatic trials in the earlier and 93 in the later period. Although we did not observe a differential increase among the safety outcome trials of all categories, those in critical care settings had significantly increased in time. So did the safety outcome trials with primary outcome measures like death, myocardial infarction, and stroke as well as randomized controlled trials with a pragmatic design. These raise the issue of autonomy related to how clearly the sought-after safety through designing empirical studies primarily to quantitate harm had been worded to the trial participants in plain language. We maintain this issue cannot be adequately addressed unless the informed consent forms, especially for safety outcome trials, are in the public domain.
- 25 January 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-10
Open AccessSafety outcome trials in four mainline medical journals 30 years apart: a narrative review and the need for the transparency of informed consents
It was our impression that safety outcome trials were getting more frequent, raising ethical issues mainly related to patient autonomy. We and others had also proposed this autonomy would be best served if wording of the informed consents would be in the public domain. Initially two observers and an arbiter tabulated the main aims of randomized controlled trials (RCTs) published in 1990–1991 vs. 2019–2020 as efficacy, safety, or undecided in four mainline medical journals, from the websites. A pragmatic design as well as other salient features was also tabulated. After noting too many trials were categorized as undecided, two additional independent observers and the arbiter did a reassessment. In our reassessment of 889 RCTs, 309 in earlier and 580 in the later time period, 828 (93%) were categorized as efficacy and 47 (5%) as a safety trial. We were undecided in 14 (2%) trials. The proportion of safety outcome trials between the two time periods were similar [14/309 (5%) vs. 33/580 (6%)] while RCTs of any category conducted in the critical care settings notably increased in time [12/309 (4%) vs. 52/580 (9%) OR 2.4; 1.3–4.6]. Death was a primary outcome measure in 0/14 among the earlier and 16/33 (49%) among the later safety outcome trials. Stroke in 9 and myocardial infarction in 8 safety outcome trials were additional primary outcome measures in the same group. There were 2 pragmatic trials in the earlier and 93 in the later period. Although we did not observe a differential increase among the safety outcome trials of all categories, those in critical care settings had significantly increased in time. So did the safety outcome trials with primary outcome measures like death, myocardial infarction, and stroke as well as randomized controlled trials with a pragmatic design. These raise the issue of autonomy related to how clearly the sought-after safety through designing empirical studies primarily to quantitate harm had been worded to the trial participants in plain language. We maintain this issue cannot be adequately addressed unless the informed consent forms, especially for safety outcome trials, are in the public domain.
- Open Access
- 14 October 2024
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 11 (3) , 364-370
Factors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study
Objective: To evaluate the development of anti-drug antibodies (ADAb) against tumor necrosis factor inhibitors (TNFi) therapy during a 2-year period and search the factors linked to patients with axial spondyloarthritis (axSpA). Methods: Biologic-naive patients with axSpA were included in this observational study. Serum drug levels and ADAb were measured at weeks 12, 24, 52, and 104 of treatment by enzyme-linked immunosorbent assay (ELISA). The development of ADAb and factors related to ADAb over time were investigated using generalized estimating equations (GEE). Results: A total of 180 patients with axSpA (116 male, mean (±SD) 45.6 (±11.9) years) who started TNFi treatment (etanercept (32.2%), adalimumab (27.2%), golimumab (20.6%), infliximab (20%)) were included. In the etanercept treatment group, only 1 patient had ADAb at 12 weeks and 24 weeks. Anti-drug antibodies against TNFi drugs were present in the adalimumab group in 32.7% of patients and in the infliximab group in 21.2% of patients at 12 weeks, and the proportion of ADAb-positive patients were found to be stable throughout the follow-up for adalimumab- and infliximab-treated patients. In the golimumab group, one patient had ADAb against golimumab at 12 weeks and the proportion of ADAb-positive patients increased throughout follow-up. In longitudinal analysis, baseline age, TNFi type, longitudinal Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and ASDAS-CRP scores, serum C-eeactive protein (CRP) levels, presence of adverse events and treatment discontinuation were associated with the presence of ADAb. Conclusion: The development of ADAb against TNFi therapy is associated with younger age, high disease activity, the development of adverse events and more common treatment discontinuation in patients with axSpA during 2-year follow-up. Cite this article as: Ediboğlu ED, Çınar M, Kozacı D, et al. Factors associated with the development of anti-drug antibodies to TNFi and the consequences for axial spondyloarthritis; A two-year follow-up study. Eur J Rheumatol. 2024;11(3):364-370.
- 14 October 2024
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 11 (3) , 364-370
Open AccessFactors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study
Objective: To evaluate the development of anti-drug antibodies (ADAb) against tumor necrosis factor inhibitors (TNFi) therapy during a 2-year period and search the factors linked to patients with axial spondyloarthritis (axSpA). Methods: Biologic-naive patients with axSpA were included in this observational study. Serum drug levels and ADAb were measured at weeks 12, 24, 52, and 104 of treatment by enzyme-linked immunosorbent assay (ELISA). The development of ADAb and factors related to ADAb over time were investigated using generalized estimating equations (GEE). Results: A total of 180 patients with axSpA (116 male, mean (±SD) 45.6 (±11.9) years) who started TNFi treatment (etanercept (32.2%), adalimumab (27.2%), golimumab (20.6%), infliximab (20%)) were included. In the etanercept treatment group, only 1 patient had ADAb at 12 weeks and 24 weeks. Anti-drug antibodies against TNFi drugs were present in the adalimumab group in 32.7% of patients and in the infliximab group in 21.2% of patients at 12 weeks, and the proportion of ADAb-positive patients were found to be stable throughout the follow-up for adalimumab- and infliximab-treated patients. In the golimumab group, one patient had ADAb against golimumab at 12 weeks and the proportion of ADAb-positive patients increased throughout follow-up. In longitudinal analysis, baseline age, TNFi type, longitudinal Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and ASDAS-CRP scores, serum C-eeactive protein (CRP) levels, presence of adverse events and treatment discontinuation were associated with the presence of ADAb. Conclusion: The development of ADAb against TNFi therapy is associated with younger age, high disease activity, the development of adverse events and more common treatment discontinuation in patients with axSpA during 2-year follow-up. Cite this article as: Ediboğlu ED, Çınar M, Kozacı D, et al. Factors associated with the development of anti-drug antibodies to TNFi and the consequences for axial spondyloarthritis; A two-year follow-up study. Eur J Rheumatol. 2024;11(3):364-370.
- 11 May 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (3) , 1309-1315
Validation of the Behçet’s Syndrome Overall Damage Index (BODI) for retrospective studies and a proposal for modification
Objective: Assessment of damage accrual over time is important for evaluating and comparing long-term results of treatment modalities and strategies. Retrospective studies may be useful for assessing long-term damage, especially in rare diseases. We aimed to validate Behçet’s Syndrome Overall Damage Index (BODI) for use in retrospective studies by evaluating its construct validity, reliability and feasibility in retrospectively collected data. Additionally, we aimed to determine missing items by evaluating Behçet’s syndrome patients with different types of organ involvement and long-term follow-up. Methods: We included 300 patients who had at least two clinic visits at 1-year intervals. The construct validity for use in retrospective trials was assessed by comparing BODI scores calculated from patient charts and during face-to-face visits. BODI was additionally scored using retrospective chart data by two different observers and by the same observer six months apart, in a blinded manner. The time for filling BODI was evaluated to assess feasibility. Additionally, damaged items that were missing from BODI were identified. Results: There was a good correlation between the retrospective and face-to-face evaluation of BODI (ICC 0.99; %95 CI 0.99–0.99). Inter-observer and intra-observer agreement were good (ICC 0.96 and 1, respectively). The main damage items that BODI did not capture were hypertension, liver failure, lung parenchymal involvement, glaucoma and lymphedema. Conclusion: BODI seems to be a reliable and feasible instrument for assessing damage in retrospective studies. Modifying BODI using the additional damage items identified in this study may make it an even better scale.
- 11 May 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (3) , 1309-1315
Validation of the Behçet’s Syndrome Overall Damage Index (BODI) for retrospective studies and a proposal for modification
Objective: Assessment of damage accrual over time is important for evaluating and comparing long-term results of treatment modalities and strategies. Retrospective studies may be useful for assessing long-term damage, especially in rare diseases. We aimed to validate Behçet’s Syndrome Overall Damage Index (BODI) for use in retrospective studies by evaluating its construct validity, reliability and feasibility in retrospectively collected data. Additionally, we aimed to determine missing items by evaluating Behçet’s syndrome patients with different types of organ involvement and long-term follow-up. Methods: We included 300 patients who had at least two clinic visits at 1-year intervals. The construct validity for use in retrospective trials was assessed by comparing BODI scores calculated from patient charts and during face-to-face visits. BODI was additionally scored using retrospective chart data by two different observers and by the same observer six months apart, in a blinded manner. The time for filling BODI was evaluated to assess feasibility. Additionally, damaged items that were missing from BODI were identified. Results: There was a good correlation between the retrospective and face-to-face evaluation of BODI (ICC 0.99; %95 CI 0.99–0.99). Inter-observer and intra-observer agreement were good (ICC 0.96 and 1, respectively). The main damage items that BODI did not capture were hypertension, liver failure, lung parenchymal involvement, glaucoma and lymphedema. Conclusion: BODI seems to be a reliable and feasible instrument for assessing damage in retrospective studies. Modifying BODI using the additional damage items identified in this study may make it an even better scale.
- 23 November 2023
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 26 (1) , 1-11
Disease and Treatment-Specific Complications of Behçet Syndrome
Purpose of Review We aimed to highlight disease-related and treatment-related complications of Behçet syndrome (BS) based on previous and recent studies and our own experience. Recent Findings The Behçet’s Disease Overall Damage Index is a newly developed instrument to assess damage in BS. Validation studies showed that damage is already present in some patients at diagnosis and continues to progress during the follow-up, mainly related to treatment complications. Nervous system and eye involvement are important causes of long-term disability. Cyclophosphamide seems to be associated with infertility and an increased risk of malignancies among BS patients, prompting the consideration of shortening the treatment duration. Flares in mucocutaneous manifestations have been reported with tocilizumab, and de novo BS manifestations with secukinumab therapy. Summary Earlier diagnosis and treatment are essential to prevent disease-related damage in BS. Treatment-related complications seem to be the leading cause of damage during the disease course.
- 23 November 2023
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 26 (1) , 1-11
Disease and Treatment-Specific Complications of Behçet Syndrome
Purpose of Review We aimed to highlight disease-related and treatment-related complications of Behçet syndrome (BS) based on previous and recent studies and our own experience. Recent Findings The Behçet’s Disease Overall Damage Index is a newly developed instrument to assess damage in BS. Validation studies showed that damage is already present in some patients at diagnosis and continues to progress during the follow-up, mainly related to treatment complications. Nervous system and eye involvement are important causes of long-term disability. Cyclophosphamide seems to be associated with infertility and an increased risk of malignancies among BS patients, prompting the consideration of shortening the treatment duration. Flares in mucocutaneous manifestations have been reported with tocilizumab, and de novo BS manifestations with secukinumab therapy. Summary Earlier diagnosis and treatment are essential to prevent disease-related damage in BS. Treatment-related complications seem to be the leading cause of damage during the disease course.